选取早期DN的患者60例,在原有治疗的基础上,给以依帕司他150mg/d,罗格列酮4mg/d,治疗12个月,并在治疗前后检测UAER、BP、BMI、BUN、Scr、FPG、血脂、HbA1c、CRP、IL-6、TNF-a水平。结果:治疗前后患者FPG、血脂、BP、BMI、BUN、Scr、HbA1c没有显著变化(P>0.05),治疗后UAER比治疗前明显下降(P<0.01),治疗后血清炎症因子水平较治疗前明显下降(P<0.01)。结论:依帕司他联合罗格列酮能够阻抑早期糖尿病肾病病情的发展。 Sixty patients with early DN were selected and treated with epalrestat 150 mg / d and rosiglitazone 4 mg / d for 12 months. UAER, BP, BMI and BUN were measured before and after treatment , Scr, FPG, blood lipid, HbA1c, CRP, IL-6, TNF-a levels. Results: Before and after treatment, there was no significant change in FPG, BP, BMI, BUN, Scr and HbA1c in patients with UAER after treatment (P <0.01), but the level of serum inflammatory cytokines Significantly decreased (P <0.01). Conclusion: Epalrestat combined with rosiglitazone can inhibit the development of early diabetic nephropathy.